BioPharmSignal logoBioPharmSignal

Biotech News

SAB BIO to Participate in Upcoming Investor Conferences

SAB Biotherapeutics (SABS)SAB BiotherapeuticsCompany update

MIAMI, March 02, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team

Related news

SABSSAB Biotherapeutics2026-08-06 11:30 EST

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

SABSSAB Biotherapeutics2026-05-29 12:00 EST

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

APGEApogee Therapeutics2026-05-28 20:01 EST

Apogee Therapeutics to Participate in Upcoming June Conferences

XGNExagen2026-07-28 13:00 EST

Exagen Inc. to Participate in Upcoming Investor Conference

KNSAKiniksa2026-05-29 20:01 EST

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

ARGXArgenx2026-05-27 05:00 EST

argenx to Present at Upcoming Investor Conferences

IFRXInflarx NV2026-08-20 11:30 EST

InflaRx Announces Participation in September Investor Conferences

AVTXAvalo Therapeutics2026-07-22 11:00 EST

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

AVTXAvalo Therapeutics2026-07-07 11:00 EST

Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

EQEquillium, Inc.2026-05-28 20:05 EST

Equillium to Participate in the 2026 Jefferies Global Healthcare Conference

View all latest news

SAB Biotherapeutics

Fully Human Polyclonal Antibodies SAB Biotherapeutics uses genetically engineered cattle to produce large quantities of fully human polyclonal antibodies. SAB-142 SAB-142 is a human anti-thymocyte immunoglobulin intended to preserve insulin-producing beta-cell function in newly diagnosed type 1 diabetes. SAFEGUARD The registrational...

Recent company news

SABSSAB Biotherapeutics2026-08-06 11:30 EST

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

SABSSAB Biotherapeutics2026-07-30 12:30 EST

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

SABSSAB Biotherapeutics2026-07-07 12:00 EST

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

SABSSAB Biotherapeutics2026-05-29 12:00 EST

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

SABSSAB Biotherapeutics2026-05-12 11:30 EST

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Stock data

Close
3.78 USD
Market cap
266.1M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States